{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:11:04Z","timestamp":1787015464078,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T00:00:00Z","timestamp":1374537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Guidelines identify a 3\u2010month topical application of an ultra\u2010potent corticosteroid ointment as the mainstay of medical treatment for vulvar lichen sclerosus (\n                      <jats:styled-content style=\"fixed-case\">VLS<\/jats:styled-content>\n                      ). However, there are no trials providing evidence that any specific corticosteroid is superior to another.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To assess the effectiveness and safety of a 12\u2010week application of mometasone furoate (\n                      <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content>\n                      ) 0.1% ointment, with a tapering regimen, in achieving control of\n                      <jats:styled-content style=\"fixed-case\">VLS<\/jats:styled-content>\n                      signs and symptoms and to detect potential risk factors for\n                      <jats:styled-content style=\"fixed-case\">VLS<\/jats:styled-content>\n                      non\u2010response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      147 patients affected with\n                      <jats:styled-content style=\"fixed-case\">VLS<\/jats:styled-content>\n                      were enrolled in a 12\u2010week active treatment phase (\n                      <jats:styled-content style=\"fixed-case\">ATP<\/jats:styled-content>\n                      ) with topical 0.1%\n                      <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content>\n                      . The primary efficacy endpoint was the rate of patients achieving clinical response, as defined by protocol parameters. The secondary efficacy endpoint was to assess the changes of mean\n                      <jats:styled-content style=\"fixed-case\">VLS<\/jats:styled-content>\n                      \u2010related symptoms after the 12\u2010week\n                      <jats:styled-content style=\"fixed-case\">ATP<\/jats:styled-content>\n                      compared with baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      By the end of the\n                      <jats:styled-content style=\"fixed-case\">ATP<\/jats:styled-content>\n                      , 113 patients (80.7%) experienced a treatment response, whereas 27 women (19.3%) were judged as non\u2010responders. Mean symptom scores decreased significantly in the study patients, regardless of their clinical response at the end of the\n                      <jats:styled-content style=\"fixed-case\">ATP<\/jats:styled-content>\n                      . Among all the epidemiological and clinical data considered, only the absence of previous medical therapies was found to be related to a significantly higher risk of non\u2010response to treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Application of 0.1%\n                      <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content>\n                      ointment for 12\u00a0weeks on a tapering regimen was found to be an effective and safe therapy option in the\n                      <jats:styled-content style=\"fixed-case\">ATP<\/jats:styled-content>\n                      of\n                      <jats:styled-content style=\"fixed-case\">VLS<\/jats:styled-content>\n                      and could represent an alternative first\u2010line treatment to an ultra\u2010potent molecule.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.12219","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T09:23:32Z","timestamp":1374657812000},"page":"943-948","source":"Crossref","is-referenced-by-count":21,"title":["Mometasone fuoroate 0.1% ointment in the treatment of vulvar lichen sclerosus: a study of efficacy and safety on a large cohort of patients"],"prefix":"10.1111","volume":"28","author":[{"given":"A.","family":"Virgili","sequence":"first","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Ferrara Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Borghi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Ferrara Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Minghetti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Ferrara Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Corazza","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Section of Dermatology University of Ferrara Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,23]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90060-8"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)08228-2"},{"key":"e_1_2_5_4_1","first-page":"9","article-title":"Lichen sclerosus et atrophicus","volume":"57","author":"Wallace HJ","year":"1971","journal-title":"Trans St Johns Hosp Dermatol Soc"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.024"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405020-00005"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01211.x"},{"key":"e_1_2_5_8_1","first-page":"161","article-title":"Fibrogenic cytokines in vulvar lichen sclerosus. An immunohistochemical study","volume":"42","author":"Carli P","year":"1997","journal-title":"J Reprod Med"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04004.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.044"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09997.x"},{"key":"e_1_2_5_12_1","first-page":"CD008240","article-title":"Topical interventions for genital lichen sclerosus","volume":"12","author":"Chi CC","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.011"},{"key":"e_1_2_5_14_1","first-page":"37","article-title":"Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation","volume":"38","author":"Bracco GL","year":"1993","journal-title":"J Reprod Med"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2010.01142.x"},{"key":"e_1_2_5_16_1","first-page":"621","article-title":"Lichen sclerosus of the vulva. Long\u2010term steroid maintenance therapy","volume":"44","author":"Sinha P","year":"1999","journal-title":"J Reprod Med"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0171"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07446.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12273"},{"key":"e_1_2_5_20_1","first-page":"444","article-title":"Topical mometasone furoate for vulvar lichen sclerosus","volume":"48","author":"Cattaneo A","year":"2003","journal-title":"J Reprod Med"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200101000-00062"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.6.709"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.6.702"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(01)01496-X"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-199512000-00008"},{"key":"e_1_2_5_26_1","first-page":"790","article-title":"Lichen sclerosus. Therapy with clobetasol propionate","volume":"43","author":"Lorenz B","year":"1998","journal-title":"J Reprod Med"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12219","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:53:43Z","timestamp":1695542023000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,23]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/jdv.12219"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12219","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,23]]}}}